login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Actilyse authorised in the UK for treatment of ischaemic stroke patients presenting within 4.5 hours after stroke onset


Wednesday, 11 Apr 2012 15:57
Paul Guyler
Paul Guyler


On 14 March, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised the use of the recombinant tissue plasminogen activator (rt-PA) alteplase (Actilyse, Boehringer Ingelheim) for the thrombolytic treatment of acute ischaemic stroke up to 4.5 hours after symptom onset, and after prior exclusion of intracranial haemorrhage. Previously, alteplase was authorised for a 3 hour treatment window. 


The extended treatment window from 3 to 4.5 hours will allow a greater number of eligible patients to receive thrombolysis. Data from Rudd AG et al (Journal of Neurology, Neurosurgery and Psychiatry 2011; 82: 14-19) and Bembenek J et al (International Journal of Stroke 2010; 5: 430) suggest that extension of the licence has the potential to make alteplase treatment available to between 2–4.7% more people with acute stroke.

Paul Guyler, lead stroke clinician, Southend University Hospital NHS Trust and lead for Acute Stroke, Essex Cardiac and Stroke Network, UK, said: “The 4.5 hour approval will allow clinicians to treat more patients and therefore improve their clinical outcomes. We have made great strides in improving stroke services in the UK, but we must now consider the extended treatment window and adjust protocols so they continue to apply best practice for prompt diagnosis, assessment for eligibility, and delivery of thrombolysis.”


Martin James, consultant stroke physician, The Royal Devon and Exeter NHS Foundation Trust, and former president, British Association of Stroke Physicians, said: “Extending the licensed time window for thrombolysis treatment with alteplase to 4.5 hours from onset represents a major step forward in the treatment of acute ischaemic stroke. However, excitement at this significant advance is moderated by the widely held concern that by having more time in which to deliver treatment, clinicians may lose some of the sense of urgency that came with the previous tight 3 hour window. Our research has shown that if the time window extension results in even a small general delay for all treated patients, then the benefits from extension could be lost (James M et al, International Journal of Stroke, 2011; 6 (suppl 2): 4). Eliminating in-hospital delays to treatment, for example by using pre-alerts to stroke teams and radiology departments and rapid assessment protocols, is the most effective way to increase the number of patients who survive stroke free of disability.”


The revised alteplase licence indication is based on the results of the European Cooperative Acute Stroke Study (ECASS 3), a randomised, double-blind, placebo controlled trial published in the New England Journal of Medicine in 2008. ECASS 3 demonstrated that Actilyse can increase favourable outcomes with only minimal or no disability after an acute ischaemic stroke when administered in an extended time-window from 3 to 4.5 hours after symptom onset.




Add New Comment

Most popular


ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Friday, 11 Jul 2014
This new patent grants six claims surrounding the use of the company’s Barrel vascular reconstruction device technology platform. New US patent for Barrel vascular reconstruction device

InspireMD announces completion of CGuard CARENET trial
Wednesday, 09 Jul 2014
Enrolment is complete in the CARENET trial, which is assessing the peri-procedural safety and efficacy of CGuard systems in the treatment of carotid lesions. InspireMD announces completion of CGuard CARENET trial

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

William T Couldwell
Thursday, 24 Apr 2014
William T Couldwell is professor of neurosurgery in the Department of Neurological Surgery, U... William T Couldwell

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions